# TIXiMED

> UAB spinout developing TIX100, an oral TXNIP inhibitor for Type 1 diabetes.

## Why it is interesting

Most T1D care is insulin management; TIXiMED is pushing a disease-modifying oral bet on TXNIP inhibition from UAB Comprehensive Diabetes Center science — with Helmsley Charitable Trust PRIs totaling multi-million non-dilutive capital and First Avenue Ventures co-founder involvement.

## Profile

- **Stage:** other
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-26

## Key facts

- Helmsley Charitable Trust PRI (Dec 2024): $2.65M loan to initiate clinical trials of TIX100
- Oral TXNIP inhibitor (TIX100) for Type 1 diabetes; FDA IND path into first-in-human studies
- UAB spinout founded 2021; co-founded with First Avenue Ventures’ Michael Goodrich
- Phase 1 SAD study completed; Phase 1b MAD work and expanded Helmsley PRI reported

## Investors in our directory

- https://venturecapitaltracker.com/fund/first-avenue-ventures

## Related articles

- https://venturecapitaltracker.com/birmingham-al-startups-and-vc-firms-2026

---
Source: https://venturecapitaltracker.com/startup/tiximed